Suchergebnisse - "Frisell, Thomas"

PubPharm (6)

1

COVID-19 clinical outcomes and DMT of MS patients and population-based controls

enthalten in: Annals of clinical and translational neurology | 2022

von Longinetti, E. | Bower, H. | McKay, K. | +15

2

Influenza outcomes in patients with inflammatory joint diseases and DMARDs : how do they compare to those of COVID-19?

enthalten in: Annals of the rheumatic diseases | 2022

von Bower, H. | Frisell, T. | Di Giuseppe, D. | +2

3

COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls

enthalten in: Annals of Clinical and Translational Neurology | 2022

von Longinetti, E. | Bower, H. | McKay, K. | +15

4

Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden : from infection severity to impact on care provision

enthalten in: RMD open | 2021

von Bower, H. | Frisell, T. | di Giuseppe, D. | +26

ErratumIn: RMD Open. 2022 Jan;8(1):. - PMID 35042729

5

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden

enthalten in: JAMA network open | 2021

von McKay, K. | Piehl, F. | Englund, S. | +4

6

Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population : a nationwide Swedish cohort study

enthalten in: Annals of the rheumatic diseases | 2021

von Bower, H. | Frisell, T. | Di Giuseppe, D. | +14

CommentIn: Ann Rheum Dis. 2023 Nov;82(11):e223. - PMID 34226191

1
[1]